PCSK9 Inhibitor AK102 Tested Against High-Risk Hypercholesterolemia in Phase 2 Trial
Akeso's AK102 faces a placebo-controlled test in high-cardiovascular-risk patients already on statins and ezetimibe.
Summary
High LDL cholesterol remains one of the strongest modifiable risk factors for cardiovascular disease, yet many patients fail to reach target levels even on maximum statin therapy. AK102 is a PCSK9 inhibitor developed by Akeso, a class of drugs that block a protein responsible for degrading LDL receptors in the liver, thereby allowing more cholesterol to be cleared from the bloodstream. This completed Phase 2 trial enrolled patients with hypercholesterolemia at very high or high cardiovascular risk, randomizing them to AK102 or placebo on top of existing statin and/or ezetimibe therapy. The double-blind, placebo-controlled, multicenter design is considered the gold standard for evaluating new drugs. Results from this study will help determine whether AK102 offers a safe and effective alternative or addition to existing PCSK9 inhibitors like evolocumab and alirocumab.
Detailed Summary
Elevated LDL cholesterol is a leading driver of atherosclerosis and cardiovascular events, contributing to millions of deaths annually. Despite the availability of statins, many high-risk patients do not achieve guideline-recommended LDL targets, leaving a significant treatment gap that newer therapeutic classes must fill. PCSK9 inhibitors have emerged as a powerful option in this space, and AK102 represents a next-generation candidate in this drug class from Chinese biopharmaceutical company Akeso.
This Phase 2 study was a double-blind, randomized, placebo-controlled, multicenter trial evaluating AK102 in patients with hypercholesterolemia who were at very high or high cardiovascular risk. Participants received AK102 or placebo on top of background therapy with statins and/or ezetimibe, reflecting real-world clinical practice where combination lipid-lowering is standard of care.
The primary objective was to assess the efficacy of AK102 in reducing cholesterol levels in this high-risk population. Safety was also a co-objective, as any new therapeutic entering an established drug class must demonstrate a clean tolerability profile to compete with approved agents. The trial has been completed, though full results have not been publicly detailed in the available abstract.
The implications for clinical practice could be significant. If AK102 demonstrates LDL-lowering efficacy comparable to approved PCSK9 inhibitors, it could expand access to this drug class, particularly in markets where cost and availability limit current options. Competition in the PCSK9 inhibitor space may also drive down costs, benefiting patients globally.
However, several caveats apply. The full dataset has not been published in peer-reviewed form based on available information, and this is a Phase 2 study, meaning larger Phase 3 trials would be required before regulatory approval. The long-term cardiovascular outcomes benefit of AK102 specifically remains unproven.
Key Findings
- AK102, a PCSK9 inhibitor, was tested in Phase 2 against high-cardiovascular-risk patients on background statin/ezetimibe therapy.
- The trial used a rigorous double-blind, placebo-controlled, multicenter design considered gold standard for efficacy evaluation.
- The study is completed, suggesting efficacy and safety data exist but are not yet fully detailed in the public abstract.
- AK102 targets patients who fail to reach LDL goals despite existing lipid-lowering therapy — a common clinical challenge.
- Positive Phase 2 results could position AK102 as a competitive, potentially lower-cost alternative to evolocumab and alirocumab.
Methodology
This was a Phase 2, double-blind, randomized, placebo-controlled, multicenter study enrolling hypercholesterolemia patients at very high or high cardiovascular risk. Participants received AK102 alongside background lipid-lowering therapy (statins and/or ezetimibe). The trial sponsor is Akeso, and the study status is listed as completed.
Study Limitations
This summary is based on the abstract only, as the full study data are not publicly available, limiting assessment of effect sizes, adverse events, and patient demographics. As a Phase 2 trial, this study is not powered or designed to detect cardiovascular outcomes benefits. The sponsor, Akeso, is the study funder, which introduces potential for industry bias.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.